Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer
Overexpression of hypoxia-inducible factor-1 alpha is noted during the invasive and metastatic process of transitional cell carcinoma. It will upregulate vascular endothelial growth factor (VEGF) and drive proliferation, invasiveness, metastasis, and antiapoptotic ability of cancer cells. We propose...
Main Authors: | Chia-Lun Wu, Szu-Yuan Ping, Cheng-Ping Yu, Dah-Shyong Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-04-01
|
Series: | Kaohsiung Journal of Medical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1607551X11001410 |
Similar Items
-
Metastatic Melanoma to the Bladder: Case Report and Review of the Literature
by: Rohit V. Patil, et al.
Published: (2017-02-01) -
Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer
by: Arshia Beigi, et al.
Published: (2021-09-01) -
Chemotherapy of metastatic colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01) -
Predictive nomograms for early death in metastatic bladder cancer
by: Tao Chen, et al.
Published: (2023-01-01) -
Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
by: Hong-Chen Qu, et al.
Published: (2020-01-01)